At the Retina Society meeting, Dr. Mark R. Barakat discussed the positive results of the 26-week interim analysis for Ixo-vec gene therapy in treating neovascular age-related macular degeneration. The phase 2 LUNA study showed that Ixo-vec reduced treatment burden in previously treated patients at two doses and was well tolerated. Barakat highlighted the effectiveness of local steroid prophylaxis in combination with the therapy. The study results were presented at the conference, and Barakat is both an investigator and consultant for Adverum Biotechnologies.
Source link
Ixo-vec for neovascular AMD shows treatment burden reduction at 26 weeks
